BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Globe Newswire•29/10/2026•07:00 ET
0
Key Highlights
- ➤Four HAE portfolio abstracts accepted for presentation at ACAAI’s 2026 Annual Scientific Meeting
- ➤Navenibart long-term safety, efficacy, and quality-of-life interim results scheduled for presentation
- ➤Three ORLADEYO abstracts cover healthcare utilization, switching outcomes, and pediatric dose adjustments
- ➤Navenibart is being evaluated for potential HAE prophylaxis dosing every 3 or 6 months
—New data highlight BioCryst's commitment to advancing a portfolio of therapies for people living with HAE—
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that four abstracts from its hereditary angioedema (HAE) portfolio have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting taking place in Phoenix, Arizona, November 12-16.
Get started
Create a free account to read the full story.